Search This Blog

Friday, September 18, 2020

European advisory group back Pfizer’s Neulasta biosimilar

The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Pfizer’s (NYSE:PFE) Nyvepria (pegfilgrastim), a biosimilar to Amgen’s (NASDAQ:AMGN) Neulasta.

A final decision from the European Commission usually takes ~60 days.

https://seekingalpha.com/news/3615272-european-advisory-group-back-pfizers-neulasta-biosimilar

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.